Connect with us

General News

Chronic Cannabis Use and Liver Cancer

Published

on

liver cancer

Analysts from the University of Arkansas for Medical Science investigated the effects of cannabis compound, cannabidiol, on the livers of mice. According to the results, people who regularly consume the compound have greater chances of developing liver cancer.

The study appears in the Journal Molecules. It suggests that even though cannabidiol is good for relieving pain in comparison to painkillers, it is harmful to liver. Examiners at the University of Arkansas for Medical Science gave various doses of the compound to the mice under study. They gave lower doses to some mice, while they administered more doses to other mice.

Scientists used a new term for the various doses given to the mice

They gave them a technical term, ‘Mouse Equivalent Doses’ (MED) that suggested optimum dose in human maintenance in EPIDIOLEX. The dose was equal to 20 milligrams per kilogram weight.

The results were surprising. Scientists found that the mice they gave larger doses of CBD to had signs of liver toxicity within a day.

What did the results indicate?

After noting those results, they found that two-thirds of the mice in the subacute stage were either dead or were about to die within a week of the consumption. The scientists went into in-depth analysis and analyzed mice that were administered with different doses of CBD or mouse equivalent doses.

The study finds that the compound CBD in cannabis can intervene in the drug and nutrient interactive process.

CBD differentially influences around fifty genetic variants. They were in association with oxidative stress response due to more than normal free radicals. These free radicals resulted because of the response of the body. In addition to that, there was also some association found in the lipid metabolic pathway and enzymes that were involved in drug metabolism.

Previous studies do not show unanimous results about the effect of cannabis on liver

Previous researches have shown that there are certain components of cannabis that are hazardous to the liver. Out of these researches, on the contrary, one study suggested that the compound reverse the damage.

The liver damage, in that case, points to the damage done as a result of alcohol abuse, like fatty liver disease. In other cases, the compound further worsened the signs.

Moreover, hepatitis C patients who consumed cannabis showed more scars on the liver tissues than those who didn’t consume it. There was a general progression of the viral disease. Doctors are concerned that there might be certain components of cannabis that can result in liver diseases such as fatty liver diseases.

However, there is a dire need to study the effects of the compound on the liver on bigger levels, so there is no misunderstanding. At this point, it is not ideal to believe in a few types of research.

Government funding for researches is essential to provide a bigger framework and capital for more beneficial studies. However, the products for cannabis that are legal in the market do not pose such serious threats to the liver health of the consumers.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

General News

Global Alliance for Cannabis Commerce announces GACC Certified™ testing

Published

on

The Global Alliance for Cannabis Commerce (GACC) provides policymakers and legislators with the guidance necessary to take the nascent cannabis industry from the gray market into a global provider of medical and adult-use cannabis products.

Recently, the Company announced the launch of a nationwide, voluntary industry certification standard for safety and purity in cannabis product testing. The aim of this program is to provide licensed sellers and consumer confidence that the legal products are safe and they meet the purity standards. By the end of 2020, this program will be available to all state-licensed cannabis operations.

The Executive Director at GACC, Randal John Meyer says that with the current laws it is impossible to make sure that there are uniform standards for purity. Furthermore, GACC President Rezwan Khan added, ”GACC wants to establish a means by which consumers can have confidence in the products they buy and to provide the industry the tools to give this assurance.”

GACC and the member of the companies believe in establishing standards for safety and purity, and in creating a serious and effective testing program. Nominations for membership on the Standards Committee (terms are two years) will be open to the public beginning on Thursday, December 5, 2019, and closing on January 30, 2020.

The Board of GACC will determine the initial composition. Future members will include public nominations and will be determined by the GACCAST Standards Committee and reviewed by the GACC Board of Directors. It is expected that the GACCAST Standards Committee will take approximately nine months to establish the initial standards and protocols so that implementation can begin in 2020.

Brands such as Raw Garden, DNA Genetics, Crockett Family Farms, Urbn Leaf, La Familia, and Team Elite Genetics, and all derivative cannabis products from DNA Genetics’ and Crockett Family Farms’ genetic have pledged to support the development of the standards setting protocol and to adopt and implement it as well when it is effective.

To accommodate the entire legal cannabis industry’s access to this program, GACC will be creating a membership class, the Standard Membership, which involves minimal costs for participation, and that will provide access to the GACC Certified™ Program. GACC is also planning to arrange for testing discounts for members who use the GACC network of laboratories. The GACC President Rezwan Khan added, “Our goal is to ensure this program isn’t cost-prohibitive for any cannabis companies of any size.”

Solo sciences will be offering GACC members a substantial discount on anti-counterfeiting, instant product recall solo*CODE™ technology as they have previously partnered with GACC to ensure that medical patients and adult consumers do not unwittingly purchase counterfeit or illicit vape products.

On this account, the Executive Director of GACC added, “The combination of the voluntary GACC Certified™ consumer safety standard, particularly when combined with members’ access to substantially discounted solo*CODE™ anticounterfeiting technology, allows GACC members to provide their consumers with the confidence they need that anywhere in the United States they legally purchase a participating cannabis product, our blue leaf means it’s safe and genuine.”

Continue Reading

General News

Pasha Brand’s Board Restructuring, announces resignations

Published

on

Pasha Brands Ltd. is one of North America’s largest network and aggregator of craft cannabis. Recently, the Company announced the following resignations: Scott WaltersRosy Mondin and Hugo Alves as directors of the Company. Pasha Brand thanked them for their contributions, time, and efforts.

The Executive Chairman, Patrick Brauckmann stated, ”I’m grateful Scott, Rosy and Hugo shared my vision and were able to contribute to our unique offering. Their resignations will not diminish our resolve to see this project completed, as thousands of cannabis professionals wait in line to re-enter the industry they created.”
However, the resignations are effective immediately.

The Company is now working on establishing a new working board. The idea behind a new board is to solely include people who invested in the brand and its future. The Company’s vision includes giving opportunities for small farmers, legacy brands, the brands excluded by the government, and the founders of Canada’s original cannabis industry. This will help the companies to enter the business world through Pasha’s craft aggregation platform.

Pasha Brand as a Company has proven its capabilities in cannabis cultivation, genetic research and development, product processing, and retail. This makes the Company uniquely positioned in the new legal cannabis market through its network of hundreds of craft cannabis suppliers. Given the opportunity, the brand also plans on refreshing the ranks and reposition the key personnel to reflect the Company’s goal of having Grizzlers™ and Roll Model™ pre-rolls in the market in early 2020.

The Company has many accomplishments under its brand name. Pasha Brand has acquired 8 pre-legalization brands. It established BC Craft Supply Co, which is a solution provider to the micro cultivation community is Canada. It acquired Medcann Health Products Ltd. The Medcann Health Company is a  Health Canada licensed cultivator and processor operating out of a 10,000 square foot facility on Vancouver Island. Another one of the acquired brands is Royal Green Acres Ltd., which is a late stage licensed producer applicant under the ACMPR. The Company established a proprietory platform bringing quality assurance to the craft industry by the name of Craft Labs™.

The Pasha Brand’s common shares trade on the CSE under the symbol “CRFT” and on the FSE under the symbol “ZZD”. Commenting on these changed, the Executive Chairman, Patrick Brauckmann mentioned that he wants a Company that works on the principle of quality and meaning. The Company recruited a strong group of cannabis professionals, brokers and operators, many of who played a part in creating Canada’s original cannabis industry to continue living up to its standards.

Continue Reading

Cannabis

HempMeds® announces partnership with Sezzle, Offers New Payment Solution

Published

on

Medical Marijuana, Inc, the first company to receive historic import permits for CBD products from the governments of BrazilMexicoArgentina, and Paraguay has recently announced a partnership of its subsidiary HempMeds with Sezzel, a leading alternative digital payment platform.

Located in U.S, the first ever publicly traded cannabis company Medical Marijuana inc. has also recently launched a new line of cannabis-derived nutraceutical products, brands and supply chain. As its subsidiary, HempMeds is a corporate portfolio company which is also the Company’s master distributor and contracted marketing company, handling sales and distribution.

Sezzle, a leading alternative digital payment platform offers customers cutting-edge payment alternatives. HempMeds® customers can choose Sezzle at checkout to delay full payment for their items, at zero percent interest. Consumers receive their items right away and Sezzle pays merchant upfront and assumes all repayment risk. It requires a 25 percent down payment at the time of purchase and the remaining balance is automatically scheduled as three equal-installment payments to be paid every two weeks.

President Todd Morrow of HempMeds said that their aim is to provide better services so everyone with a tight budget can afford the benefits. Sezzle offers a “buy-now, pay-later” service that does not require shoppers to enter into a traditional loan or pay any upfront fees or interest. Sezzle is certified up to PCI DSS Level 1 as a Service Provider. He further stated, “Partnering with Sezzle means that we can provide our customers with an easy way to lift some of the financial burden during this expensive time of year.”

HempMeds® was the first company to ever bring hemp-based cannabidiol (CBD) oil products to market in the U.S. and was also the first to make CBD products available in bulk for U.S. consumers. It was also the first-ever company to receive historic federal government import approvals for its CBD products in the nations, as well as the first to have its CBD products listed in the Prescribers’ Digital Reference and one of the first to be certified by the U.S. Hemp Authority.

Medical Marijuana, Inc. CEO Dr. Stuart Titus mentioned, “With the number of new consumers becoming interested in purchasing CBD, we believe that Sezzle is a great opportunity to make our CBD products more accessible to people of all socioeconomic backgrounds.” The number of people searching for e-commerce outlets to purchase CBD has increased every year since 2017. Researchers found that online search volume for CBD in the U.S. increased 160.4 percent in 2018 compared with 2017 and is expected to increase by 117.7 percent in 2019 compared to 2018.

Continue Reading

Trending